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a  b  s  t  r  a  c  t
Recurrent  squamous  cell  carcinoma  of  the  head  and  neck  (SCCHN)  carries  a poor  prognosis.  Tumor
hypoxia  (TH)  has  been  implicated  as one  of  many  factors  contributing  to  SCCHN  recurrence.  TH  leads
to  radiation  resistance  by reversing  radiation-induced  DNA damage.  Effective  strategies  to  overcome
TH  may  improve  outcomes  in patients  with  SCCHN.  We  searched  the  English  literature  on  PubMed  and
Abbreviations: ARCON, accelerated radiotherapy with carbogen and nicotinamide; cAMP, cyclic adenosine monophosphate; CA4P, combretastatin A-4 phosphate; CAIX,
arbonic anhydrase IX; CNS, central nervous system; CT, computed tomography; CTLA4, cytotoxic T-lymphocyte associated antigen 4; DCE, dynamic contrast-enhanced;
MXAA, 5, 6-dimethylxanthenone-4-acetic acid; DNA, deoxyribonucleic acid; EGFR, epidermal growth factor receptor; EPO, erythropoietin; ESA, erythropoietin stimulat-
ng  agent; FAZA, [18F]ﬂuoroazomycin arabinoside; FETA, [18F]ﬂuoroetanidazole; FETNIM, [18F]ﬂuoroerythronitroimidazole; FMISO, [18F]ﬂuoromisonidazole; Gd-DTPA,
adopentetate dimeglumine; GLUT, glucose transporter; HBO, hyperbaric oxyge; HER2, human epidermal growth factor receptor-2; HIF-1, hypoxia inducible factor-1;
PV,  human papilloma virus; HSP, heat shock protein; IRE, inositol-requiring enzyme; LRC, loco-regional control; MHC, major histocompatibility complex; MIC, MHC  class
 chain-related; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; mTOR, mammalian target of rapamycin; NK, natural killer; NO, nitric oxide; OS,
verall  survival; PET, positron emission tomography; PD-L1, programmed death ligand-1; RCC, renal cell carcinoma; RNA, ribonucleic acid; SCCHN, squamous cell carcinoma
f  the head and neck; TH, tumor hypoxia; UPR, unfolded protein response; VDA, vascular disrupting agent; VEGF, vascular endothelial growth factor; VHL, von Hippel-Lindau.
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reviewed  the reference  sections  of  key  articles  related  to  TH  (publications  spanning  from  the  early  1900s
to  the present).  We  summarized  the  underlying  theory  of TH in  SCCHN,  methods  for  quantifying  it,  and
the numerous  therapies  developed  to  modulate  it.  We  included  articles  that  set  the  foundation  of  TH  as
a  theory  and  the  most  relevant  articles  published  within  the  last  15  years  related  to  TH quantiﬁcation
and  therapeutic  targeting.  Despite  extensive  research,  targeting  TH  in SCCHN  has  not  become  a part  of
routine  clinical  practice  in North  America,  and  we  analyze  the  pitfalls  in  hypoxia  research  that  have led
to this  failure.  We  propose  that  future  studies  should  test  a combined  approach  of targeting  the  immune
system in addition  to cellular  pathways  rendered  aberrant  in  TH  and  should  include  development  of novel
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. Introduction
Tumor hypoxia (TH) in human malignancies is associated with
nferior patient outcomes (Nordsmark et al., 2005). TH is present
n most, if not all, squamous cell carcinomas of the head and neck
SCCHN), yet TH-directed therapy has not become a routine part
f clinical care despite extensive research. To summarize the cur-
ent understanding of TH in SCCHN and to propose a way  forward,
e focus this review on three main areas: 1) the evidence support-
ng TH’s role in radioresistance; 2) methods for quantifying TH;
nd, 3) existing and emerging therapies targeting TH in SCCHN,
ith an examination of why many of these treatments have failed.
e  propose a way to overcome failure of TH-targeted therapy by
mproving our understanding of TH-induced immunomodulation.
mmune-based therapy in combination with TH-targeted drugs is
n area ripe for further research.
. Theory of tumor hypoxia and radioresistance
TH’s inﬂuence on radiation response as a theory was  ﬁrst pro-
osed by Schwartz in 1909 when he used vascular compression
o induce “anemia” in tissues. Radiation associated skin toxicity
as reduced, allowing delivery of a higher dose to deep tumors
Kaplan, 1979). Thomlinson and Gray later hypothesized that TH
mpacted radiation response by conferring radioresistance (Gray
t al., 1953). Analysis of cylindrical tumor sections suggested that
xygen diffused a maximum distance of 150–200 m from a blood
essel (later determined to be a maximum of 70 m)  (Hall, 2000).
hey reasoned that cells located beyond this distance are anoxic
nd therefore undergo cell death; however, cells near this necrotic
one, at the outer limit of oxygen diffusion, are hypoxic, relatively
adioresistant, retain the ability to form new tumors, and poten-
ially could survive after a course of radiation, leading to tumor
epopulation and disease relapse.
Elegant work by Powers and Tolmach (1963) generated cell
urvival-radiation dose curves under hypoxic conditions using
hree groups of lymphosarcoma-bearing mice exposed to room
ir or 100% oxygen during radiation. Using mathematical extrap-
lation from the cell survival curves of each group, an average
f 15% radioresistant hypoxic cells was found in tumors radiated
nder air-breathing (normal) conditions. This experiment provided
n vivo evidence of the existence of hypoxic, radioresistant cell pop-
lations (Powers and Tolmach, 1963; Moulder and Rockwell, 1984).
TH likely confers radioresistance because of “radical competi-
ion.” As depicted in Fig. 1, DNA radicals generated by radiation
xposure are “ﬁxed” in a damaged state by oxygen forming perox-
des with DNA, leading to cell death. In the absence of oxygen, DNA
adicals may  be reduced by hydrogen donation from sulfhydryl
roups on glutathione or other thiol compounds, leading to radio-
rotection and cell survival (Zeman, 2009). Certain compounds,blished  by  Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
such as nitroimidazoles, mimic  the effect of oxygen, leading to
radiosensitization and cell death even in hypoxic tissues.
Blood vessel density and orientation, shunting within tumors
and alterations in red cell membrane physiology in response to
hypoxia are factors that contribute to TH (Dewhirst et al., 2008).
Hypoxic fractions have been observed to change within a matter
of hours in some tumors (Kallman, 1972), implying that transient
alterations in the blood supply lead to TH (Brown, 1979). Such alter-
ations in blood supply could increase the fraction of hypoxic cells,
leading to detrimental effects on radiation response.
In recent years, many additional TH-induced changes in tumor
biology, including alterations in gene expression, receptor sig-
nalling via tyrosine kinases, angiogenesis, apoptosis and immune
function, have been recognized (Wilson and Hay, 2011). The degree
to which modiﬁcations in these pathways confer radioresistance
has not been well characterized. Therapies investigated to date
therefore have been based on limited data obtained in an earlier era.
Methods to improve oxygen delivery or mimic  the effect of oxygen
within tumors as means of overcoming hypoxia-driven radiore-
sistance reﬂect an earlier, less nuanced view of TH.  The failure
of most TH-directed therapies to meaningfully alter clinical out-
comes might be explained by this lack of understanding, as will be
discussed further below.
3. Quantifying tumor hypoxia
SCCHN TH can be quantiﬁed with several methods, including
oxygen electrodes inserted directly into tumors, staining of tumors
with endogenous and exogenous markers, and TH imaging. The
ideal technique, yet to be found, would be minimally to non-
invasive, does not consume oxygen or disrupt oxygen distribution
within the tumor, has high resolution spatially and temporally,
and is non-toxic. An overview of these methods is provided in
Table 1, and reviews have been published previously (Hoogsteen
et al., 2007; Pacheco-Torres and Lopez-Larrubia Ballesteros et al.,
2011; Bache et al., 2008). Each detection method has its pros and
cons, but none is being used clinically.
Oxygen electrodes, while providing a direct measurement of TH,
may  miss regional variations in oxygen tension or redistribute/alter
oxygenation within the tumor due to their large size. Non-invasive
methods such as exogenous and endogenous marker staining avoid
this concern. Exogenous TH detection methods involve administra-
tion of nitroimidazoles, compounds that form adducts with thiol
groups on amino acids in hypoxic areas, prior to tumor biopsy or
surgical excision. Endogenous TH detection consists of immuno-
histochemical staining of TH markers, including hypoxia inducible
factor-1 (HIF-1), erythropoietin, carbonic anhydrase IX (CAIX),
glucose transporters (GLUT-1, GLUT-3), osteopontin and erythro-
poietin (EPO). Radiographic methods for measuring TH are less
invasive than electrodes and exogenous/endogenous techniques,
holding promise for more widespread clinical use.
88 K.K. Curtis et al. / Critical Reviews in Oncology/Hematology 103 (2016) 86–98
Fig. 1. Oxygen stabilizes DNA damage induced by radiation by forming peroxide compounds with DNA, leading to apoptosis. Hypoxia, intracellular thiol compounds and/or
exogenously administered compounds (such as glutathione) reduce DNA radicals, leading to cell survival. Nitroimidazoles mimic  oxygen’s effect, leading to DNA peroxide
formation and apoptosis. Adapted from Zeman EM.  Biologic basics of radiation oncology. In: Gunderson L.L., Tepper J.E., editors. Clinical Radiation Oncology. Philadelphia:
Churchill Livingstone; 2009. p 3–46.
Table 1
Methods to detect tumor hypoxia and correlation with clinical outcomes in published studies.
Method Marker Outcome Reference
Oxygen electrode Intratumor oxygen concentration Inferior OS Nordsmark et al. (2005); Rudat
et al. (2000); Rudat et al. (2001)
Exogenous tumor staining Pimonidazole Inferior LRC and DFS Kaanders et al. (2002c)
EF5 Inferior DFS Evans et al. (2007)
Endogenous tumor staining HIF-1,  CAIX, OPN Inferior LRC, OS Bache et al., (2008)
GLUT-1, GLUT-3 Inferior DFS, OS Baer et al. (2002); Mineta et al.
(2002)
DLL4 Improved RFS Kuhnert et al. (2011)
EPO Inferior OS Lin et al. (2012)
Hypoxia gene signature Inferior LRC, MFS, RFS Buffa et al. (2010); Betts et al.

































eFS, disease free survival; LRC, loco-regional control; MFS, metastasis free survival;
A novel approach to studying TH endogenously is array based
roﬁling of hypoxia gene signatures. Buffa and colleagues devel-
ped a gene expression signature enriched for hypoxia genes,
hich correlated with metastasis-free and recurrence-free survival
n a cohort of SCCHN patients (Buffa et al., 2010). Betts and oth-
rs reported the results of a study wherein tumor samples from
0 SCCHN patients were subject to gene analysis using a Taqman
ow Density Array (developed based on data from Buffa et al. and
omprised of 26 previously published hypoxia genes expressed in
CCHN). Gene signature results were compared to pimonidazole
taining. The authors concluded that gene expression proﬁling was
ensitive for detecting TH and had lower intra-tumor heterogeneity
han was observed with pimonidazole staining (Betts et al., 2013).
Gene signature proﬁling may  be useful for predicting treatment
esponse. Toustrup and others validated a 15-gene hypoxia classi-
er using in vitro and in vivo methods. It was then validated using
23 biopsies from SCCHN patients enrolled in a Danish study of
adiation with nimorazole or placebo. Patients with “more hypoxic”
umors based on gene signature proﬁle who received nimorazole
ad better 5-year loco-regional failure (54%) than patients with
more hypoxic” tumors randomized to placebo (21%, p = 0.0001).
he authors believed that the gene signature set could identify
atients with hypoxic tumors who might beneﬁt from hypoxia
odiﬁcation (Toustrup et al., 2011). Clatot and others validated a
ene expression proﬁle in which the over-expression of 9 genes,
ncluding 3 related to TH (HIF1, CAIX and DLL4), correlated
ith inferior metastasis-free survival (Clatot et al., 2014). Ongoing
rospective trials are evaluating hypoxia gene expression proﬁling
n SCCHN patients undergoing chemoradiation (Bethesda, 2013).
lthough gene proﬁling as a predictive biomarker for response to
H-modifying therapy is appealing, cost and reproducibility may
e barriers to widespread clinical use. Signiﬁcant advances in the
echnology of studying gene expression proﬁle in recent years may
ower the cost in the near future to allow clinical trials to further
valuate the value of such approach to design targeted treatment(2013); Toustrup et al. (2011);
Clatot et al. (2014)
verall survival; RFS, recurrence free survival.
against TH, similar to what has been performed for genetic assays
used in early stage breast cancer (Blohmer et al., 2013), and non-
small cell lung cancer (Roth et al., 2014).
Radiographic methods for measuring TH are less inva-
sive than exogenous or endogenous techniques and even-
tually may  become more widely used. Positron emission
tomography (PET) imaging, when combined with nitroimida-
zoles chemically modiﬁed to contain a radionuclide group,
can be used to quantify TH. [18F]ﬂuoromisonidazole (FMISO),
[18F]ﬂuoroazomycin arabinoside (FAZA), [18F]ﬂuoroetanidazole
(FETA) and [18F]ﬂuoroerythronitroimidazole (FETNIM) are com-
mon  nitroimidazole agents administered with PET. Hypoxic areas
in human tumors in vivo are visible using such PET tracers (Krause
et al., 2006). Lung, SCCHN and prostate cancers were among the
ﬁrst tumor types shown to contain regional hypoxia by FMISO-
based imaging (Rasey et al., 1996). In one study of SCCHN patients,
pre-treatment FMISO PET predicted survival (Rajendran et al.,
2006). It also predicted response to radiation and local progression-
free survival (Kikuchi et al., 2011). Limitations of FMISO-based
imaging include slow uptake into tumors, lack of contrast with
background tissue and accumulation of radioactive byproducts
(Gronroos and Minn, 2007). One study of FETNIM-based imaging
in SCCHN reported a trend toward inferior OS with higher FETNIM
uptake prior to radiation therapy (Lehtio et al., 2004). FAZA-based
imaging was studied in 11 patients with SCCHN. FAZA uptake was
conﬁrmed in 7 of 11 primary tumors and 3 of 11 lymph node metas-
tases, although uptake in the kidney and hepatobiliary tree and a
mean tumor-to-muscle uptake ratio of 2.3 ± 0.3 were seen as limi-
tations to use of this tracer (Souvatzoglou et al., 2007). No tracer is
felt to be superior for radionuclide-based PET imaging; tracers are
selected based on their availability and tumor type. For example,
FMISO appears most promising in SCCHN, whereas FAZA may  have
a greater role in central nervous system (CNS) tumors (Chitneni
et al., 2011).

























































Existing approaches to targeting SCCHN tumor hypoxia.
Therapeutic Target Therapy
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PET combined with other imaging modalities may  give addi-
ional insight into the tumor microenvironment and the presence
f TH. Gadopentetate dimeglumine (Gd-DTPA)-based dynamic
ontrast-enhanced magnetic resonance imaging (DCE-MRI) allows
or assessment of blood perfusion, permeability of tumor vascula-
ure, and ﬂuid volume approximations (Yankeelov and Gore, 2009).
hen combined with FMISO PET and studied in 13 node-positive
CCHN patients, FMISO uptake negatively correlated with tumor
erfusion as assessed by DCE-MRI. This result further supports the
ypothesis that tumors contain hypoxic areas, and that such areas
re created, at least in part, by poor perfusion (Jansen et al., 2010).
Novel nitroimidazole compounds in combination with mag-
etic resonance spectroscopy (MRS) are being studied. SR-4554
nd TF-MISO, both ﬂuorinated nitroimidazole derivatives, have
een studied in vivo in a variety of tumors. SR-4554 signal inten-
ity correlated with pO2 measurements in animal models, and has
ntered Phase I clinical trials, where it has been well tolerated and
emonstrated retention within tumors (Pacheco-Torres and Lopez-
arrubia Ballesteros et al., 2011; Seddon et al., 2002; Lee et al.,
009). TF-MISO has not yet been studied in humans, but pre-clinical
ata suggest it is retained in hypoxic tumors (Procissi et al., 2007).
ne advantage of magnetic resonance techniques is better spatial
esolution of TH than PET provides.
Several studies have attempted to correlate hypoxia tumor
maging results with immunohistochemical markers of hypoxia,
ut have yielded conﬂicting results. In one study of 15 SCCHN
atients treated with radiation, no correlation between FETNIM
maging results and endogenous expression of hypoxia markers
uch as HIF-1 and GLUT-1 was found (Gronroos et al., 2014). Other
tudies have found correlations between FMISO results and HIF-
 staining (Norikane et al., 2014; Sato et al., 2013). Studies to
xamine the optimal timing of hypoxia imaging during radiation
or SCCHN also have been conducted, based on the hypothesis that
ypoxia imaging results can be used to increase radiation doses to
ypoxic tumors not responding during treatment (Bollineni et al.,
014). However, larger validation studies of these techniques will
e needed before they can be implemented in routine clinical prac-
ice.
To summarize, hypoxia imaging techniques are not validated
ufﬁciently and their use should be limited as investigational
ools. Including hypoxia imaging in future studies of TH-targeted
herapies would be useful to further validate this technique in iden-
ifying patients for TH-directed therapy, as well as to help conﬁrm
n investigational drug’s activity on hypoxia pathway(s). Cost-
ffectiveness of hypoxia imaging is an important factor to consider
hen considering widespread clinical application of the technique.
. Current techniques for targeting TH
A systematic review and meta-analysis of studies including
805 patients with SCCHN found signiﬁcant improvements in
RC (OR 0.71, 95% CI 0.63–0.80, p < 0.001) and OS (OR 0.87,
5% CI 0.77–0.98, p = 0.03) with hypoxic modiﬁcation combined
ith radiation (Overgaard, 2011). This evidence suggests hypoxic
odiﬁcation probably alters SCCHN tumor biology in clinically
eaningful ways. Hypoxic modiﬁcation strategies that have been
nvestigated in clinical trials are listed in Tables 2 and 3, and
ill be reviewed here. Note that none of the strategies listed in
ables 2A and 3 have become part of routine clinical practice.
.1. Hyperbaric oxygenHyperbaric oxygen (HBO) is believed to improve oxygen deliv-
ry to hypoxic tissues, leading to radiosensitization and therapeutic
ffect (Table 3). Patients breathe 100% oxygen at a pressure aboveARCON, accelerated radiotherapy with carbogen and nicotinamide; ESAs, erythro-
poietin stimulating agents.
1 atmosphere in an enclosed chamber for 20–30 min prior to radi-
ation. The technique was  abandoned in the 1980s largely due
to space and physical requirements of HBO-based radiation and
because oral agents targeting TH became available. Enthusiasm also
was dampened by an accident involving explosive decompression
of a chamber (Tobin, 1971). Any beneﬁt to HBO likely is offset by
increased risk of seizures and radiation tissue injury (Bennett et al.,
2005).
4.2. Hyperthermia
Several studies show hyperthermia favorably impacts TH. Ran-
domized trials of hyperthermia with or without radiation in SCCHN
patients showed improved LRC (OR 2.88, 95% CI 1.28–3.39) for com-
bined treatment. Three trials demonstrated improvement in OS,
but one trial reported an increase in late toxicity (Horsman and
Overgaard, 2007; Datta et al., 1990; Valdagni and Amichetti, 1993;
Huilgol et al., 2010). Newer hyperthermia delivery techniques are
being studied, which may  prompt additional clinical trials in SCCHN
(Hurwitz, 2010).
4.3. Blood transfusion
Up to 64% of SCCHN patients were classiﬁed as anemic in one
trial (Lee et al., 1995) and anemia is almost universal during a course
of chemoradiation (Rosen et al., 2003). Lower oxygen carrying
capacity theoretically could worsen TH and increase radioresis-
tance. Pre-treatment and/or post-treatment anemia is prognostic
for LRC and OS in SCCHN, with an approximate 10% decrease in
loco-regional control for every 2 g/dL decrease in hemoglobin (Hu
and Harrison, 2005). Radiosensitivity was improved in anemic mice
given blood transfusions (Hirst and Wood, 1987; Hill et al., 1971).
However, clinical trials evaluating the beneﬁt of blood transfusion
prior to or during radiation, though few in number, do not support
it as a means to improve loco-regional control, disease-free sur-
vival or overall survival, as shown in Table 3. Pre-radiation blood
transfusion has not been adopted in routine clinical practice and is
not being studied actively at this time.
4.4. Erythropoietin stimulating agents (ESAs)
As with blood transfusion, preclinical models demonstrated
improvement in anemia-related radioresistance with ESA use
(Stuben et al., 2003). A retrospective analysis of 191 patients
with SCCHN treated over a 10-year period with chemoradiation
and surgery found that patients given recombinant erythropoi-
etin (EPO) for a pre-chemoradiation hemoglobin value less than
14.5 g/dL had signiﬁcantly higher 2-year LRC and OS than patients
with similar hemoglobin values not given EPO (Glaser et al., 2001).
Subsequently, 2 randomized trials and a systematic review found
inferior outcomes with ESA use in SCCHN, as shown in Table 3. The























Clinical studies of select tumor hypoxia-modifying treatments in SCCHN.
Therapy Study Design No. Patients Outcome Limitations Reference(s)
Hyperbaric oxygen Systematic review of trials 2286 5-year mortality RRR 0.82
(p = 0.03);
NNT = 5;
5-year RR improved LC 0.77
(p = 0.01)
Included studies comparing conventional
fractionation RT (without HBO) to HBO with
hypofractionated RT; hypofractionation may
have produced hypoxic sensitization; unclear
from available evidence if HBO with
conventional RT has a clinical beneﬁt;
heterogeneity of TH within tumors may limit
effect of HBO on disease biology
Bennett et al. (2005)
Blood transfusion RCT: transfusion for pre-radiation
hemoglobin <13 g/dL (women) or
<14.5 g/dL (men) versus no
transfusion prior to RT
414 No improvement in LRC, DFS, OS;
patients without anemia had
improved LRC
A sub-randomization of a RCT comparing
nimorazole plus RT to RT alone; may  lack
power
Hoff et al. (2011a)
Blood transfusion Pooled analysis of 2 RCT:
transfusion for pre-radiation
hemoglobin <3 g/dL (women) or
<14.5 g/dL (men) versus no
transfusion prior to RT
1166 No improvement in LRC, DFS, OS Low hemoglobin may be marker of a worse
overall clinical condition that cannot be
compensated by blood transfusion
Hoff et al. (2011b)
ESAs RCT: EPO vs. no EPO for
hemoglobin ≤13.5 g/dL (men) or
12.5 g/dL (women) prior to RT
148 3-year LRC, LRPFS, OS not
improved; trend for better LRC in
control arm
Study prematurely closed (futility determined
at  interim analysis); trial not designed
speciﬁcally to evaluate inferior outcomes with
ESA
Machtay et al. (2007)
ESAs RCT: epoetin beta vs. placebo for
hemoglobin <120 g/L (women) or
130 g/L (men) prior to and during
RT
351 Inferior LRPFS (RR 1.62, p = 0.0008);
inferior OS (RR 1.39, p = 0.02) with
epoetin beta
Patients undergoing both deﬁnitive RT and
adjuvant RT (for both completely and
incompletely resected disease) included
Henke et al. (2003)
ESAs Systematic review of RCT 1397 Inferior OS  (OR 0.73, p = 0.005);
inferior LRPFS (OR 0.63, p = 0.0002)
with EPO
Inferior outcomes with EPO may be from
treating to a higher hemoglobin concentration
Lambin et al. (2009)
ARCON Single arm, single institution
prospective study
51 2-year actuarial LC 92%; 2-year
actuarial OS 85%
16% of patients discontinued inhaled carbogen
and 33% discontinued nicotinamide during the
study (nausea/vomiting)
Kaanders et al. (1998)
ARCON Single arm, single institution
prospective study
215 3-year actuarial LC better for
larynx and oropharynx (80% and
88%) than for hypopharynx and
oral cavity (69% and 37%)
31% discontinued nicotinamide during the
study (nausea/vomiting)
Kaanders et al. (2002b)
ARCON Multi-institution RCT of
accelerated radiotherapy alone
versus ARCON
345 No improvement in 5-year LC,
laryngeal preservation, DFS and
OS;
5-year regional control improved
with ARCON (93% versus 86%,
p  = 0.04).
Requirement for and timing of neck dissection
for  non-CR after RT not speciﬁed; regional
failure rates may be inaccurate if patients
undergoing required “salvage” neck
dissections after RT were not counted as
failures; heterogeneity of TH within tumors
may  limit effect of ARCON on disease biology
Janssens et al. (2011)
ARCON Translational side study of a
multi-institution RCT;
pimonidazole administered prior
to  primary tumor biopsy
79 Regional control improved and
trend toward improved 5-year DFS
among ARCON-treated patients
with hypoxic tumors (86% versus
40%, p = 0.08)
Small numbers of regional failures and
pimonidazole staining of primary tumor
(rather than regional nodes) limit conclusions
about ARCON effect on controlling hypoxic
regional disease
Janssens et al. (2012)
ARCON, accelerated radiotherapy with carbogen and nicotinamide; CR, complete response; DFS, disease free survival; ESAs, erythropoietin stimulating agents; HBO, hyperbaric oxygen; LC, local control; LRC, loco-regional control;
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nd angiogenesis factors may  explain these ﬁndings (Kjellen et al.,
006; Ribatti et al., 1999). Another possibility is that tumor oxygen
elivery actually is impaired when hemoglobin levels are increased
o 14–15 g/dL as a result of microcirculation blockage by relative
olycythemia (Machtay et al., 2007). ESAs are not recommended
or SCCHN patients being treated with curative intent radiation.
.5. Agents targeting tumor blood ﬂow
Pentoxifylline, a methylxanthine derivative, decreases ﬁb-
inogen levels and increases intracellular cyclic adenosine
onophosphate (cAMP), thereby altering cell rigidity (Aviado and
orter, 1984; Ward and Pentoxifylline, 1987). Blood viscosity
herefore decreases and erythrocyte ﬂexibility increases, thereby
heoretically improving tumor blood ﬂow. Most trials evaluated
entoxifylline as a radiosensitizer in combination with oxygen,
icotinamide and radiation, with disappointing results (Johnson
t al., 1998; Stewart et al., 1997; Kwon et al., 2000). No clinical trials
f pentoxifylline as a radiosensitizer or radioprotector for SCCHN
reatment are ongoing presently.
.6. Targeting hypoxic cells—bioreductive drugs
Compounds that have selective activity in hypoxic environ-
ents are referred to as “bioreductive prodrugs.” They are reduced
n hypoxic environments to an active superoxide state, while
emaining oxidized and inert in normoxic environments, resulting
n hypoxia-selective cytotoxicity. Such compounds must contain 1
f 5 unique structures (nitro groups, quinones, aromatic or aliphatic
-oxides or a transition metal) to be reduced selectively in hypoxic
nvironments (Wilson and Hay, 2011). Examples include tira-
azamine (containing an aromatic N-oxide group), banoxantrone
aliphatic N-oxide group), apaziquone (quinone group) and PR-104
nitro group). Banoxantrone and PR-104 are discussed further in
art 5. Nitroimidazoles also are classiﬁed as bioreductive prodrugs
nd will be reviewed in more detail below.
Tirapazamine has been investigated in Phase III trials in both
CCHN and cervical cancer. Neither of these trials demonstrated
 beneﬁt when the drug was added to cisplatin and radiation in
nselected patients (Rischin et al., 2010; DiSilvestro et al., 2014).
nother Phase III trial of tirapazamine with radiation in SCCHN
as closed early due to excess mortality in the tirapazamine group
Seiwert et al., 2007). It is unclear what contributed to the observed
xcess deaths since the trial results have not been published.
.7. Radiosensitization
Nitroimidazoles are classiﬁed as bioreductive prodrugs, pos-
essing both cytotoxic and radiosensitizing properties. They
ontain aromatic heterocycle di-N-oxide groups and a lipophilic
ydrocarbon side chain. The nitrogen atoms in the molecule, hav-
ng an electron afﬁnity similar to oxygen, confer radiosensitizing
roperties. With ionization induced by radiation, the molecule is
educed, in turn delivering oxidative damage to DNA, an oxygen-
imetic effect. Metronidazole, misonidazole and etanidazole were
mong the ﬁrst nitroimidazoles studied for clinical use but proved
nsuitable (Table 4).
Nimorazole, a 5-nitroimidazole, has demonstrated clinical efﬁ-
acy in randomized studies. A Danish phase III trial (DAHANCA
-85) of 414 patients undergoing radiation for pharynx and supra-
lottic larynx cancer showed 5-year LRC of 49% with nimorazole
ompared to 33% among placebo-treated patients (p < 0.002). non-signiﬁcant improvement in OS was observed among
imorazole-treated patients (OR 1.32, 95% CI, 0.84–2.05; 10-year
ctuarial survival 26% with nimorazole versus 10% with placebo,
 = 0.32). The most common side effects included nausea and vom-ogy/Hematology 103 (2016) 86–98 91
iting (26%), ﬂushing (12%) and a transient skin rash (8%) (Overgaard
et al., 1998). No randomized studies have compared nimorazole
plus radiation to other radiosensitizers, such as cisplatin or cetux-
imab, plus radiation. Use of nimorazole has not been adopted for
treatment of SCCHN outside of Denmark, likely due to a lack of data
showing superiority of nimorazole over other chemotherapeutic
drugs, as well as to established practice patterns favoring plat-
inum agents as radiosensitizers in most of the world. A randomized
study comparing accelerated radiotherapy alone to accelerated
radiotherapy plus nimorazole (IAEA-HypoX) is ongoing (Bethesda,
2011).
4.8. ARCON
Accelerated radiotherapy with carbogen and nicotinamide
(ARCON) combines high concentrations of oxygen mixed with 2–5%
carbon dioxide, with oral nicotinamide 60 mg/kg daily and hyper-
fractionated radiation (Kaanders et al., 2002a). ARCON increased
oxygen enhancement ratios in mammary carcinoma, sarcoma and
SCCHN cell lines to a higher degree than in normal tissue (Horsman
et al., 1997). Phase I and II clinical trials of ARCON in SCCHN,
CNS malignancies and bladder cancer showed that the approach
was feasible. A randomized Phase III study of ARCON failed to
show meaningful improvements in outcomes compared to accel-
erated radiation alone (Table 3). However, a recent analysis of
272 histologic specimens of patients enrolled in this trial identi-
ﬁed signiﬁcantly improved 5-year locoregional control and disease
speciﬁc survival in subjects with low epidermal growth factor
receptor (EGFR) expression randomized to ARCON versus accel-
erated radiotherapy alone, suggesting EGFR expression may  be a
predictive biomarker for patients likely to beneﬁt from ARCON
(Nijkamp et al., 2013). Pre-treatment anemia (hemoglobin ≤12 g/dL
for women; ≤13.6 g/dL for men) also may  be a predictor of ARCON
beneﬁt (ﬁve-year locoregional control 79% with anemia versus 53%
without anemia, p = 0.03; disease free survival 68% versus 45%,
p = 0.04) (Janssens et al., 2014). Further study of ARCON in care-
fully selected patients (such as those with pre-treatment anemia
and without EGFR over-expression) may  be warranted. A proposed
mechanism of ARCON’s anti-tumor activity is via downregulation
of the HIF-1  pathway (Semenza, 2000). EGFR signalling upreg-
ulates this pathway (Nijkamp et al., 2013), thereby suggesting a
mechanism whereby tumors with high EGFR expression overcome
the effects of ARCON. Animal experiments evaluating the role of
EGFR-dependent upregulation of HIF-1 pathway are needed prior
to conducting additional human trials with this approach.
5. Emerging techniques for targeting TH
Among the TH-targeting strategies discussed in Part 4, nimora-
zole is the only agent that has been adopted for clinical use, and then
only in Denmark. A variety of emerging techniques for targeting TH
are under active investigation (Table 5).
5.1. Agents targeting tumor blood ﬂow
Vascular disrupting agents (VDAs) alter tumor blood ﬂow via
activity on the colchicine binding site on tubulin, leading to
changes in endothelial cell shape and increased vascular perme-
ability. They also may  exert cytotoxic effects on endothelial cells,
possibly through activation of apoptosis (McKeage and Baguley,
2010). Weak inter-cellular junctions and abnormalities of smooth
muscle and basement membranes in vessel walls render tumor
vasculature susceptible to VDAs (Ching et al., 2002; Baluk et al.,
2003). Combretastatin A-4 phosphate (CA4P) and AVE8062 are
two tubulin-binding VDAs among many in clinical development;
5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a ﬂavone acetic
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Table  4
Summary of nitroimidazole compounds demonstrating no meaningful clinical activity in human malignancies.
Nitroimidazole Clincal Studies Current Status Reference
Metronidazole RCT: 36 patients with supratentorial
glioblastomas
•  Metronidazole plus radiation versus
radiation alone
• 4.5 month improvement in time to
relapse/death with combination
•  Beneﬁt not better than historic controls
A commonly used antibiotic Urtasun et al. (1976)
Misonidazole 32 studies; only 5 demonstrated a beneﬁt
Neurotoxicity was dose limiting
•  Up to 80% of patients developed peripheral






Bydder et al. (1989)
Etanidazole Developed as a superior compound to
misonidazole (less lipophilic nature believed to
cause less neurotoxicity)
Phase I study showed higher doses were
possible than with misonidazole
Phase III study of 521 patients with SCCHN
• No differences in 2-year actuarial survival or
2-year actuarial locoregional control







Lee et al. (1995)
RCT, randomized controlled trial; SCCHN, squamous cell carcinoma of head and neck.
Table 5
Emerging techniques for targeting SCCHN tumor hypoxia.
Therapeutic Target Therapy



































aIF-1, hypoxia inducible factor-1; HSP90, heat shock protein 90; mTOR, mammalian
arget of Rapamune; PD-1, programmed death receptor-1; VDAs, vascular disrupting
gents.
cid analogue in clinical development, thought to induce endothe-
ial cell apoptosis and subsequent tumor hemorrhagic necrosis
McKeage and Baguley, 2010; Dvorak et al., 1988). Additionally,
MXAA may  eradicate hypoxic regions of a tumor via feedback
echanisms with tumor necrosis factor, allowing tumor reoxy-
enation and reducing radioresistance (Wilson et al., 1998). When
ombined with chemotherapy, DMXAA has shown activity in treat-
ent of NSCLC in Phase II trials (McKeage et al., 2008). Pre-clinical
arcoma models of VDAs combined with radiation or thermora-
iation have shown improved tumor response (Horsman, 2008;
urata et al., 2001; Li et al., 1998). In these models, extensive necro-
is in the center of tumors has been observed in response to VDAs
Li et al., 1998), suggesting that a hypoxic, radioresistant population
f cells may  be eliminated by the agent, rendering the remaining
iable tumor cells at the periphery sensitive to radiation. A mech-
nism of action such as this justiﬁes clinical trials of this approach,but as of this writing, VDAs combined with radiation are not being
studied in SCCHN patients.
5.2. Targeting hypoxic cells—bioreductive drugs
Aliphatic N-oxide groups on banoxantrone undergo 2-electron
reduction via cytochrome P450 enzymes (speciﬁcally CYP3A4), to
transform the molecule into a DNA intercalator and topoisomerase
II inhibitor known as AQ4. Bioreduction of the drug occurs pref-
erentially in hypoxic tumor environments where P450 enzymes
are upregulated. Once bound to DNA, AQ4 is unable to diffuse to
areas outside of tumor, thereby lessening toxicity (Papadopoulos
et al., 2008). A Phase I dose-ﬁnding trial has been completed
(Papadopoulos et al., 2008), with studies of the drug in combina-
tion with temozolomide and radiation for glioblastoma multiforme
ongoing (Bethesda, 2000). The DNA binding properties of the drug
suggest it may  have radiosensitizing properties, making a trial of
AQ4 with radiation for SCCHN an intriguing possibility.
PR-104, a dinitrobenzamide mustard, is reduced in hypoxic
environments to generate an active mustard moiety. A Phase I
study of PR-104 alone and a Phase Ib study of PR-104 in combina-
tion with gemcitabine or docetaxel, both in patients with advanced
solid tumors, have been completed (McKeage et al., 2011, 2012). In
the Phase Ib study, thrombocytopenia with gemcitabine and PR-
104 was  dose-limiting and prohibited further development of this
combination. A recommended Phase II dose was established for
docetaxel and PR-104, although the combination requires ﬁlgras-
tim support. At the recommended Phase II dose, 3 of 12 patients
had a partial response, and 2 patients had stable disease for at
least 18 weeks. Of the 42 patients treated on the trial, 4 par-
tial responses were observed, 3 of which had SCCHN histology
(McKeage et al., 2012). No active, accruing trials of PR104 are open
presently. Investigations of AQ4 and PR104 in SCCHN may  show
improved outcomes relative to past studies of bioreductive drugs,
given a different anti-tumor mechanism of action than tirapaza-
mine.



































cig. 2. Schematic of the hypoxia inducible factor 1alpha (HIF-1) pathway. In the p
on  Hippel-Lindau protein (pVHL), which in turn binds to HIF-1,  targeting it for
ranscription of genes necessary for cell survival, angiogenesis, pH regulation and c
rom: Carroll VA, Ashcroft M.  Targeting the molecular basis for tumour hypoxia. Ex
.3. Radiosensitization
Evofosfamide (formerly TH-302) is a nitroimidazole derived
rom an active metabolite of ifosfamide, further substituting
romine into positions typically occupied by chlorine in the
olecule. When reduced under hypoxic conditions, a bromo-
phosphoramide mustard agent is released, leading to DNA damage,
hile the drug remains inert in oxic cells (Hart et al., 2008; Ganjoo,
010). This agent is an excellent example of the ability of nitroimi-
azoles to confer hypoxia-selective cytotoxicity. The drug currently
s not being studied in SCCHN, but its nitroimidazole properties pro-
ide a rationale for studying evofosfamide with radiation in SCCHN
nd other tumors.
Bevacizumab, a humanized monoclonal antibody speciﬁc for
ascular endothelial growth factor (VEGF), has radiosensitizing
roperties. Pre-clinical models demonstrated impaired endothelial
ell function in response to bevacizumab, and when combined with
adiation, endothelial cell apoptosis increases and tumor angio-
enesis decreases signiﬁcantly (Hoang et al., 2012; Bozec et al.,
008). A Phase II trial of bevacizumab with cisplatin and radia-
ion for Stage III and IV SCCHN has been completed; 42 patients
eceived cisplatin 50 mg/m2 on days 1, 2, 22, 23, 43 and 44 with
evacizumab 15 mg/kg on days 1, 22 and 43, along with 70 Gy of
adiation. At 2 years, progression free survival was  75.9% (95% CI,
3.9–90.1%) and OS was 88% (95% CI, 78.6–98.4%). Toxicity did not
ppear increased compared to the historical standard of cisplatin
nd radiation (Fury et al., 2012). Another phase II study of beva-
izumab with cisplatin and cetuximab plus radiation for Stage III
nd IV SCCHN has been published, with acceptable toxicity lev-
ls and similar survival outcomes (Fury et al., 2015). In a Phase I
tudy of bevacizumab and cisplatin with radiation, hypoxia imag-
ng using Cu-diacetyl-bis(N4-methylthiosemicarbazone) PET/CT
emonstrated signiﬁcant reductions in mean SUV with beva-
izumab therapy prior to radiation and during radiation (Nyﬂotce of normoxia, prolyl-4-hydroxylase (PHDs) hydroxylates proline residues on the
itination and degradation. In low oxygen states, HIF-1 accumulates, leading to
 metabolism.
ev. Mol. Med. 2005; 7 (6): 1-16, reproduced with permission.
et al., 2015). It remains unclear from the available data whether
the therapeutic effect of bevacizumab is to reduce pathologic blood
vessel growth within tumors, thereby leading to enhanced oxy-
gen delivery and tumor responsiveness (Carmeliet and Jain, 2011;
Masunaga et al., 2011), or whether it reduces blood vessel recruit-
ment into tumors, thereby further increasing hypoxia and causing
additional tumor necrosis (Kruser et al., 2010; Williams et al.,
2007). Bevacizumab might best be used along with radiation as
de-intensiﬁed treatment for favorable risk human papilloma virus
(HPV)-related SCCHN. Preclinical models have shown upregulation
of VEGF in response to HPV infection (Tang et al., 2007), providing
the rationale to study the drug further especially in this patient
population.
5.4. Drugs targeting hypoxia-induced proteins
Cells exhibit a well-known pattern of gene activation in
response to hypoxia. HIF-1 and CAIX are transcription factors
stabilized under hypoxic conditions, leading to transcription of
genes involved in cellular metabolism, angiogenesis, invasion and
survival. As depicted in Fig. 2, the normoxic state leads to hydrox-
ylation of proline residues on von Hippel-Lindau protein (VHL) by
prolyl-4-hydroxylase. VHL in turn binds to HIF-1, targeting the pro-
tein for ubiquitination and degradation. In low oxygen states, HIF-1
accumulates, leading to gene transcription (Powis and Kirkpatrick,
2004). p53 also has been implicated in HIF-1 regulation, with loss
of p53 leading to decreased MDM-2  mediated ubiquitination and
degradation of HIF-1. Heat shock protein HSP90 plays a role in HIF-1
stabilization, since inhibitors of HSP90 lead to increased HIF-1 ubiq-
uitination and degradation (Isaacs et al., 2002). The PI3K/AKT/mTOR
pathway also has been demonstrated to regulate HIF-1 expres-
sion in some reports, but not others (Jiang et al., 2001; Hudson
et al., 2002; Alvarez-Tejado et al., 2001). In vitro and in animal
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ecreased cell migration and angiogenesis and decreased cell sur-
ival, among other effects (Bache et al., 2008). Methods of targeting
IF-1 include inhibiting the PI3K/AKT/mTOR pathway, inhibiting
SP90, and small molecules that inhibit HIF-1 stabilization (PX-
78, BAY 87-2243) (Isaacs et al., 2002; Treins et al., 2002; Zhong
t al., 2000; Minet et al., 1999; Jordan et al., 2005; Ellinghaus et al.,
011). Phase I trials of PX-478 and BAY 87-2243 are ongoing. A
hase I trial of bortezomib (decrease HIF-1 transcriptional activ-
ty) and bevacizumab showed a partial response in 4 of 91 patients
ith advanced, refractory malignancies and 7 patients with stable
isease for more than 6 months (Falchook et al., 2014).
HSP90 inhibitor trials have shown mixed results. Phase II trials
f patients with castrate-resistant prostate cancer and metastatic
elanoma were disappointing (Heath et al., 2008; Solit et al.,
008). In contrast, a phase II trial of the HSP90 inhibitor tane-
pimycin with trastuzumab for HER2 positive metastatic breast
ancer showed a combined 59% rate of complete/partial response
r stable disease, with a 22% overall response rate (Modi et al.,
011). Among 3 patients with ALK gene rearrangement-positive
dvanced NSCLC treated with the HSP90 inhibitor IPI-504, there
ere 2 partial responses and 1 stable disease (Sequist et al., 2010).
SP90 inhibitors are not being studied in SCCHN patients as of this
riting. However, trials of HSP90 inhibitors in SCCHN would be
ustiﬁed owing to their mechanism of action on HIF-1 stabilization
n areas of TH.
CAIX is a membrane associated zinc metalloenzyme involved in
onversion of carbon dioxide to bicarbonate, regulating intracellu-
ar pH in hypoxic cells reliant on glycolysis for energy production.
t also may  be involved in cell adhesion and signal transduction
Pastorekova et al., 2008). CAIX is overexpressed in solid tumors,
ncluding SCCHN, where it has been linked to tumor necrosis, higher
umor stage, and poor treatment outcome (Beasley et al., 2001;
aluz et al., 2009). HIF-1 binds to G/ACGTG sequences in DNA
hypoxia responsive elements), leading to transcription of CAIX
Kaluz et al., 2009). Phase II clinical trials of G250, a monoclonal
ntibody against CAIX, in patients with advanced renal cell carci-
oma (RCC) demonstrated median survivals up to 15 months, and
table disease in 27–30% of patients (Bleumer et al., 2004; Varga
t al., 2003). When combined with daily low-dose IL-2, 23% of
dvanced RCC patients experienced either stable disease or partial
esponse and mean survival of 22 months (Bleumer et al., 2006).
rials of G250 in the adjuvant RCC setting are ongoing. The drug is
ot being studied presently in SCCHN, but based on known over-
xpression of CAIX in SCCHN, a trial to evaluate its efﬁcacy in this
atient population may  be warranted.
Unfolded protein response (UPR) and mammalian target of
apamycin (mTOR) are two additional pathways altered by TH
nd are potential targets for therapeutic modiﬁcation. TH leads
o unfolded protein accumulation in the endoplasmic reticulum,
rompting activation of pathways to decrease protein synthesis
nd increase protein destruction (UPR) (Wouters and Koritzinsky,
008). Bortezomib, HSP90 inhibitors, and inhibitors of inositol-
equiring enzyme (IRE)-1 are examples of agents that might target
his pathway (Wilson and Hay, 2011). Cells living in energy and
utrient-deﬁcient environments modulate their activity via inhibi-
ion of mTOR complex 1, leading to an adaptive response (Koumenis
nd Wouters, 2006). Inhibition of the pathway with agents such
s rapamycin and WYE  125132 has been studied pre-clinically,
ith tumor control observed in vivo (Pencreach et al., 2009; Yu
t al., 2010). Clinical studies of these approaches are not yet
nderway..5. Autophagy
Cellular components, including proteins and organelles, are con-
erved and recycled in the endoplasmic reticulum by a processlogy/Hematology 103 (2016) 86–98
called autophagy. Recycling of cellular contents may  improve cell
survival when metabolic demands are high, as found in TH. This the-
ory is supported by ﬁndings from a murine model of SCCHN, where
TH induced autophagy, in turn reducing apoptosis (Vigneswaran
et al., 2011). In vitro, hypoxia, via HIF1, upregulates BNIP3 and
BNIP3L, genes critical to induction of autophagy (Wu  et al., 2015).
5′ adenosine monophosphate activated protein kinase also is acti-
vated under hypoxic conditions, leading to upregulation of TSC1
and TSC2, which downregulate the mTOR pathway, removing a
key inhibitor of autophagy response (Papandreou et al., 2008). UPR
also mediates autophagy. As stress on the endoplasmic reticulum to
refold proteins mounts under hypoxic conditions, autophagy path-
ways are activated (Suh et al., 2012). Antimalarial drugs such as
hydroxychloroquine, and NVP-BGT226, an inhibitor of the mTOR
pathway, have been shown to inhibit autophagy, and may  have a
role to play in SCCHN treatment (Wu et al., 2015). Several clinical
trials of hydroxychloroquine in combination with mTOR inhibitors,
proteasome inhibitors and other agents are underway in patients
with a variety of solid tumors (Bethesda, 2010).
5.6. Immune modulation
Another potential direction for targeting TH may  be through
immune modulation. Recent evidence suggests that 3 major mech-
anisms are present in TH leading to tumor immune escape: 1)
aberrations in nitric oxide (NO) signalling, which reduces NK-cell
and cytolytic T lymphocyte mediated killing; 2) TH-induced mod-
ulation of dendritic, NK and T cell activity by adenosine; and 3)
promotion of T regulatory cells by tumor associated macrophages
and other factors in the tumor microenvironment (Lee et al., 2010).
TH results in impaired NO production (McCormick et al.,
2000). Impaired NO signalling appears to increase MHC  class I
chain-related (MIC) molecule shedding, leading to downstream
immune-modulating effects. In vitro and in vivo models show
increased MIC  molecule shedding in the presence of TH, leading to
downregulated expression of the NK and T cell activating receptor
NKG2D (Doubrovina et al., 2003; Siemens et al., 2008). NO mimetics
such as glyceryl trinitrate have been shown in vivo to block HIF-1
accumulation in hypoxic cells, which in one study led to decreased
programmed death ligand-1 (PD-L1) expression and reduced inhi-
bition to cytolytic T lymphocyte killing (Barsoum et al., 2014). Taken
together, these studies suggest targeting the nitric oxide pathway
may be a mechanism to overcome TH-associated immune escape.
Regarding the second hypothesis, elevated adenosine levels
in the presence of TH may  favor maturation of dendritic cells
that stimulate a Th-0 or Th-2T cell response, possibly lead-
ing to compromised anti-tumor cytolytic T lymphocyte activity
(Panther et al., 2003). Additionally, elevated adenosine levels in
the tumor microenvironment may  inhibit T-cell receptor function
via cAMP signalling through the adenosine receptors A2AR and
A2BR, thus affecting T cell proliferation and secretion of antitumor
cytokines (Ohta et al., 2006; Sitkovsky and Ohta, 2005; Sitkovsky
et al., 2008). Adenosine also appears to inhibit NK cell activ-
ity, decreasing cytokine production and impairing perforin and
Fas ligand-mediated cytotoxic activity (Raskovalova et al., 2005;
Lokshin et al., 2006). In vitro and in vivo data show improved NK
cell activity against ovarian cancer (Hausler et al., 2011) and breast
cancer (Beavis et al., 2013) in the presence of adenosine receptor
inhibitors.
A variety of factors in the tumor microenvironment further serve
to promote a T regulatory cell response instead of a cytolytic T
cell response. TH increases macrophage colony-stimulating factor
and CC chemokine ligands 2 and 5, chemoattractants that recruit
macrophages to the tumor microenvironment. Once present,
macrophages appear to acquire a M2  phenotype, promoting a Th-2T
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013). TH also increases tumor cell production of TGF-, which has
een shown to promote regulatory T cell accumulation and pro-
iferation in the tumor microenvironment and to decrease NK cell
ctivity (Deng et al., 2013; Ghiringhelli et al., 2005).
Our understanding of how TH impacts the immune response
o tumors, together with recent clinical successes whereby anti-
umor T cell responses are improved by monoclonal antibody
herapy (Hodi et al., 2010), point toward a potential new direction
or TH-targeted therapy. To date, the vast majority of unsuc-
essful therapeutic trials targeting TH have focused on ways of
mproving radiosensitivity via increased tumor oxygenation, but
hey have paid little attention to the importance of a blunted
mmune response in the presence of TH. Perhaps what is required
s both improved oxygenation to increase radiosensitivity, as well
s immune modulation. Such a combined approach may  over-
ome our prior TH-targeted therapeutic failures. We  propose that
uture work in this area should focus on how an increase in oxy-
en tension in the tumor microenvironment modiﬁes not only
adioresponse but also immune response. By increasing tumor oxy-
enation and by targeting NO or adenosine pathways, the cytolytic
 cell response and NK cell activity may  be improved. Tumor asso-
iated macrophages and cytokine production might also be altered
y such methods. As a ﬁrst step toward testing this hypothesis,
re-clinical models should evaluate how small inhibitory RNAs to
denosine receptors, nitric oxide mimetic agents, PD-1 pathway
nhibitors, CTLA4 inhibitors, and other agents known to modulate
mmune response pathways improve radioresponse when com-
ined with oxygen mimetics such as nitroimidazoles or HIF-1
athway inhibitors. If successful, clinical trials evaluating a com-
ined approach then can be designed for a patient population
ost likely to beneﬁt. This population may  include patients with
elapsed SCCHN, where TH- and immune-modiﬁcation may be crit-
cally important. Biomarkers such as hypoxia gene signatures or
ET/MRI-based hypoxia imaging may  help to identify the appro-
riate patient population for these trials.
. Concluding remarks
As lamented by Overgaard (Overgaard, 2007), treatments tar-
eting TH are “adored and ignored.” Evidence to date demonstrates
hat simple compounds sensitize hypoxic cells to radiation effects,
enerating enthusiasm for further research on the part of clinicians
nd basic scientists. Unfortunately, a lack of funding and interest
rom drug manufacturers restricts clinical validation of such drugs.
TH biology is more complex than captured by the current models
n which such therapies are based and this may  explain the pre-
onderance of negative trials. We  lack an understanding of which
athways altered by TH are the most critical for driving tumor
rowth. Additionally, our ability to select appropriate patients for
H-targeted therapy is poor, especially because TH may  not be
rognostic in all forms of SCCHN. This point is illustrated by recent
ata suggesting HPV-related SCCHN has a similar incidence of TH
ompared to HPV-unrelated tumors, yet TH has little impact on the
xcellent prognosis of these patients (Kong et al., 2009; Trinkaus
t al., 2011). Similarly, hypoxia modiﬁcation in HPV-related SCCHN
ay not improve outcome (Lassen et al., 2010). Thus it may  appear
n a pre-clinical model that targeting TH will lead to an improved
utcome, yet if the targeted hypoxia pathway is not a key regulator
f tumor biology in a given patient, or if the therapy does not hit the
arget effectively, there would not be an improvement in treatment
utcome.
Another potential explanation for the failure of TH-targeted
herapy to improve outcomes is the heterogeneity of TH levels
ithin individual tumors. Acute blood ﬂow changes within a tumor
ay  result in tumor cells that are exposed only temporarily toogy/Hematology 103 (2016) 86–98 95
TH, setting up 2 subpopulations of hypoxic cells − those cells that
are chronically, severely hypoxic due to oxygen diffusion limita-
tions, and those cells that are temporarily hypoxic due to acute
ﬂow alterations (Janssen et al., 2005). Transient TH and subsequent
reperfusion may  be mutagenic to these cells, resulting in cells that
are viable yet also radio- and drug-resistant (Janssen et al., 2005).
Therefore, only the most severely hypoxic cells in a tumor may
respond to TH-directed therapy, whereas cells exposed temporarily
to TH are resistant to drugs or strategies aiming to improve tumor
oxygen levels. Targeting TH therefore is relevant only to a sub-
population of the tumor, rendering TH-targeting a relatively weak
strategy to fully eradicate a tumor (Wouters and Brown, 1997).
In their editorial written in the aftermath of the failed Phase
III study of ARCON, Peters and Rischin highlighted problems with
hypoxia research in SCCHN (Peters and Rischin, 2012). In the
so-called “HPV era” of SCCHN, it will be especially important to
focus hypoxia research on patients for whom it is a key driver of
tumor biology, likely those who  have HPV-negative tumors. Prior to
designing and initiating additional phase III trials in this area, it will
be critical to develop validated markers of TH. Biomarkers such as
hypoxia gene signatures or PET/MRI-based hypoxia imaging must
be included and validated in early phase trials of novel hypoxia-
targeting compounds, with the patient population of such trials
enriched for those likely to beneﬁt. Ideally, the development of gene
signature proﬁling that can be commercially available, analogous to
Oncotype DX® in guiding the use of chemotherapy for breast cancer,
would signiﬁcantly increase the chance of successful development
of a drug targeting TH. Future studies must have an appropriate
control arm, and the rationale for testing a therapy in a phase III
setting must be sound.
With additional pre-clinical studies to evaluate a combined
immune- and TH- modulating approach, our hope is that the hur-
dle of effective TH targeting may  be overcome. However, until we
have a better understanding of which TH pathways are the most
critical for driving tumor growth, as well as a deeper knowledge of
the immune system’s response in the face of TH, it remains unlikely
that TH-targeted therapy will be a part of a clinician’s therapeutic
armamentarium anytime soon. TH, known from multiple studies to
impact treatment outcomes, is an important consideration when
caring for patients with SCCHN, and ongoing research efforts to
measure and target it therapeutically are justiﬁed.
7. Conﬂict of interest
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